UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 594

Sortiert nach

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

Journal of clinical oncology, 2012-05, Vol.30 (13), p.1534-1540

2012

Link zum Volltext

Verfügbarkeit prüfen

Radium-223 mechanism of action: implications for use in treatment combinations

Nature reviews. Urology, 2019-12, Vol.16 (12), p.745-756

2019

Link zum Volltext

Verfügbarkeit prüfen

A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer

PloS one, 2022-08, Vol.17 (8), p.e0273826

2022

Link zum Volltext

Verfügbarkeit prüfen

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Journal of clinical oncology, 2008-03, Vol.26 (7), p.1148-1159

2008

Link zum Volltext

Verfügbarkeit prüfen

A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer

PloS one, 2022-08, Vol.17 (8), p.e0273826-e0273826

2022

Link zum Volltext

Verfügbarkeit prüfen

Drug Insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid

Nature clinical practice. Oncology, 2005-03, Vol.2 (3), p.150-157

2005

Link zum Volltext

Verfügbarkeit prüfen

Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients

BMC cancer, 2021-06, Vol.21 (1), p.655-655, Article 655

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

Journal of clinical oncology, 2005-06, Vol.23 (17), p.3923-3931

2005

Link zum Volltext

Verfügbarkeit prüfen

Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)

Angiogenesis (London), 2022-02, Vol.25 (1), p.47-55

2022

Link zum Volltext

Verfügbarkeit prüfen

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer

Therapeutic Advances in Urology, 2023-01, Vol.15, p.17562872231182219-17562872231182219

2023

Link zum Volltext

Verfügbarkeit prüfen

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review

Cancers, 2022-08, Vol.14 (15), p.3773

2022

Link zum Volltext

Verfügbarkeit prüfen

The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Oncology (Williston Park, N.Y.), 2016-02, Vol.30 (2), p.187-199

2016

Link zum Volltext

Verfügbarkeit prüfen

The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy With Docetaxel in Patients With Metastatic Castrate-Resistant Prostate Cancer: Results From a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance)

Cancer, 2013-10, Vol.119 (20), p.3636-3643

2013

Link zum Volltext

Verfügbarkeit prüfen

Introduction: The Changing Landscape of Prostate Cancer

Seminars in oncology, 2013-06, Vol.40 (3), p.241-243

2013

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer

Journal of clinical oncology, 2001-01, Vol.19 (1), p.44-53

2001

Link zum Volltext

Verfügbarkeit prüfen

Association between bispecific T cell engager (BiTE) therapy and inflammatory adverse effects (AEs) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14534-e14534

2023

Link zum Volltext

Verfügbarkeit prüfen

Therapy with metronomic cyclophosphamide (mCyc) in metastatic castrate resistant prostate cancer (mCRPC) and genomic correlates

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17041-e17041

2023

Link zum Volltext

Verfügbarkeit prüfen

A novel program to address acute food insecurity among patients with cancer in Philadelphia

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18739-e18739

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5105-TPS5105

2022

Link zum Volltext

Verfügbarkeit prüfen

Hormone-refractory (D3) prostate cancer: Refining the concept

Urology (Ridgewood, N.J.), 1995-08, Vol.46 (2), p.142-148

1995

Link zum Volltext

Verfügbarkeit prüfen

A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS284-TPS284

2023

Link zum Volltext

Verfügbarkeit prüfen

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2016-05, Vol.34 (14), p.1652-1659

2016

Link zum Volltext

Verfügbarkeit prüfen

Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5057-5057

2021

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.188-188

2022

Link zum Volltext

Verfügbarkeit prüfen

Advanced age and prostate cancer specific mortality among geriatric patients with metastatic prostate cancer

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.319-319

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 594

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(546)
Mit Volltextzugriff
(529)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(118)
Urology
(11)
Cancer
(10)
Jama : The Journal Of The American Medical Association
(8)
Blood
(7)
Plos One
(7)
The New England Journal Of Medicine
(7)
British Journal Of Cancer
(6)
Cancer Research
(6)
Clinical Infectious Diseases
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

Radium-223 mechanism of action: implications for use in treatment combinations

A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer

Drug Insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid

Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review

The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3

The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy With Docetaxel in Patients With Metastatic Castrate-Resistant Prostate Cancer: Results From a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance)

Introduction: The Changing Landscape of Prostate Cancer

Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer

Association between bispecific T cell engager (BiTE) therapy and inflammatory adverse effects (AEs) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Therapy with metronomic cyclophosphamide (mCyc) in metastatic castrate resistant prostate cancer (mCRPC) and genomic correlates

A novel program to address acute food insecurity among patients with cancer in Philadelphia

A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer

Hormone-refractory (D3) prostate cancer: Refining the concept

A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer

Prevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study

Advanced age and prostate cancer specific mortality among geriatric patients with metastatic prostate cancer

Suchergebnisse filtern